Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00035854 |
This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
Condition | Intervention | Phase |
---|---|---|
Bacterial Infections |
Drug: Zyvox® / Linezolid |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Single Group Assignment |
Official Title: | Linezolid IV/PO for the Treatment of Vancomycin-Resistant Enterococcus Infections in Children |
Enrollment: | 13 |
Study Start Date: | February 2002 |
Study Completion Date: | May 2004 |
Ages Eligible for Study: | up to 17 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Other specific inclusion/exclusion criteria may apply. In order to determine eligibility, further examination by the investigator is necessary.
Inclusion Criteria:
For most of the infections, 2 or more of additional symptoms are required.
Exclusion Criteria:
Study ID Numbers: | M12600082VRE, A5951062 |
Study First Received: | May 6, 2002 |
Last Updated: | August 13, 2009 |
ClinicalTrials.gov Identifier: | NCT00035854 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Pharmacia Drug Resistance, Microbial |
Bacterial Infections Anti-Infective Agents Anti-Bacterial Agents Vancomycin Linezolid |
Bacterial Infections Protein Synthesis Inhibitors Anti-Infective Agents Communicable Diseases Molecular Mechanisms of Pharmacological Action |
Therapeutic Uses Enzyme Inhibitors Infection Linezolid Pharmacologic Actions |